Germany Federal Joint Committee

Jefferies & Company has published a research report on InterMune (NASDAQ: ITMN) after Germany's Federal Joint Committee released its final assessment on Esbriet. In the report, Jefferies writes, "This morning Germany's Federal Joint Committee (G-BA) issued final assessment on clinical benefit...